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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to “L-tug 
lycopene” and reduction of blood LDL-cholesterol pursuant to Article 14 of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Lycotec Ltd, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 
via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to “L-tug 
lycopene” and reduction of blood low-density lipoprotein (LDL)-cholesterol. The food constituent that is the 
subject of the claim is L-tug lycopene (i.e. Lyc-O-Mato® embedded in fat-rich matrices by a manufacturing 
process claimed as proprietary and confidential by the applicant). The Panel considers that the food constituent, 
L-tug lycopene, which is the subject of the claim, is sufficiently characterised. The Panel considers that reduction 
of blood LDL-cholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-
cholesterol concentrations reduces the risk of CHD. The Panel notes that the unpublished studies submitted to 
support the claim were exploratory in nature and insufficient information was provided to allow the scientific 
evaluation of these studies. The Panel concludes that a cause and effect relationship has not been established 
between the consumption of L-tug lycopene and reduction of blood LDL-cholesterol. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from Lycotec Ltd, submitted pursuant to Article 14 of Regulation (EC) 
No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to “L-tug lycopene” and reduction of blood low-density lipoprotein (LDL)-
cholesterol. 
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is L-tug lycopene (i.e. Lyc-O-Mato® embedded in fat-
rich matrices by a manufacturing process claimed as proprietary and confidential by the applicant). 
The Panel considers that the food, L-tug lycopene, which is the subject of the health claim, is 
sufficiently characterised. 
The claimed effect proposed by the applicant is “decreases blood cholesterol and triglycerides levels”. 
Therefore, “L-tug lycopene” is the substance, “LDL-cholesterol” is the risk factor and “coronary heart 
disease” (CHD) is the human disease. The target population proposed by the applicant comprises 
“healthy adults who wish to lower their blood cholesterol levels”. In reply to a request from the 
European Food Safety Authority (EFSA), the applicant confirmed that the health relationship 
proposed is related to lowering LDL-cholesterol concentrations, which decreases the risk of CHD. The 
Panel considers that reduction of blood LDL-cholesterol concentrations is a beneficial physiological 
effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.  
The applicant identified eight unpublished human intervention studies as pertinent to the claim. 
The eight human intervention studies provided were conducted with L-tug lycopene in different food 
matrices, followed similar protocols, and, as indicated by the applicant, were exploratory in nature. 
The Panel notes that the information provided was insufficient to allow a scientific evaluation of the 
studies, and therefore EFSA requested that the applicant provide the full study reports. In reply, the 
applicant claimed that no additional information on the studies existed. 
From the limited information available in the application, the Panel notes that the studies were not 
randomised and that some methodological aspects, such as the definition of primary outcome(s), 
power calculations, treatment of missing data, compliance or correction for multiplicity of outcomes, 
were not considered in the study reports, possibly because of the exploratory nature of these studies, as 
claimed by the applicant. The Panel also notes that, for one of the studies, a number of discrepancies 
exist between the version provided to EFSA and the published version, regarding the number of 
subjects included, the participant flow and the presence or absence of randomisation. The Panel 
considers that no conclusions can be drawn from these studies for the scientific evaluation of the 
claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-tug lycopene and reduction of blood LDL-cholesterol. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of permitted 
claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 27/08/2014. 
 The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. 
 The scientific evaluation procedure started on 07/11/2014. 
 On 26/11/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the clock 
was stopped on 04/12/2013, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
 On 16/01/2015, EFSA received the requested information as submitted by the applicant and 
the clock was restarted. 
 During its meeting on 06/02/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related “L-tug lycopene” 
and reduction of blood LDL-cholesterol. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to “L-tug lycopene” and reduction of blood 
LDL-cholesterol. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of “L-tug lycopene”, a positive assessment of its safety, nor a decision on whether “L-tug lycopene” 
is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address 
Lycotec Ltd, 2nd Floor, The Platinum Building, St. John’s Innovation Park, Cowley Road, Cambridge 
CB4 0WS, United Kingdom. 
The application contains a request for the protection of the unpublished proprietary data study reports 
from Petyaev et al., in accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food as stated by the applicant 
According to the applicant, the food for which this health claim is made is L-tug lycopene—a 
proprietary formulation of lycopene embedded in fat-based foods. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is “significantly and dose-dependently decrease blood 
cholesterol and triglycerides levels”. Therefore, in this health claim application, L-tug lycopene is the 
substance, “LDL-cholesterol” is the risk factor and “coronary heart disease” (CHD) is the human 
disease. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “L-tug lycopene has been 
shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the development of 
coronary heart disease”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed a daily intake of 7 mg L-tug lycopene. The target population proposed 
comprises healthy adults who wish to lower their blood cholesterol levels. 
ASSESSMENT 
1. Characterisation of the food 
The applicant stated that the food that is the subject of the health claim is “L-tug lycopene”. 
L-tug lycopene is prepared from a lycopene-rich oleoresin extract obtained from ripe fruits of tomato 
(Lyc-O-Mato®, LycoRed, Beer Sheva, Israel), which is embedded in fat-based foods such as dark 
chocolate, olive oil, dairy butter and sunflower oil, following a manufacturing process described in the 
application which has been claimed as proprietary and confidential by the applicant. 
The concentration of lycopene in the final food products is measured by high-performance liquid 
chromatography (HPLC). The Panel notes that L-tug lycopene cannot be distinguished from standard 
lycopene by HPLC. 
The Panel considers that the food, L-tug lycopene (i.e. Lyc-O-Mato® embedded in fat-rich matrices 
by a manufacturing process claimed as proprietary and confidential by the applicant), which is the 
subject of the health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “decrease blood cholesterol and triglycerides levels”. 
Therefore, in this health claim application, “L-tug lycopene” is the substance, “LDL-cholesterol” is the 
risk factor and “coronary heart disease” is the human disease. The target population proposed by the 
applicant comprises “healthy adults who wish to lower their blood cholesterol levels”. In reply to a 
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request from the European Food Safety Authority (EFSA), the applicant confirmed that the health 
relationship proposed is related to lowering low-density lipoprotein (LDL)-cholesterol concentrations, 
which decreases the risk of CHD. 
CHD is a leading cause of mortality and morbidity in European populations, with over 1.9 million 
deaths in the European Union and over 4.35 million deaths in Europe each year (Pedersen et al., 
2005). Elevated blood cholesterol is an important modifiable risk factor in the development of CHD 
(WHO, 2002a, b). It has been shown that blood cholesterol concentrations can be decreased by drugs 
and by dietary and lifestyle changes (Ornish et al., 1998; Gordon, 2000; Denke, 2005; van Horn et al., 
2008). 
The Panel considers that reduction of blood LDL-cholesterol concentrations is a beneficial 
physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.  
3. Scientific substantiation of the claimed effect 
The applicant stated that, as L-tug lycopene is a recent innovation, only proprietary, unpublished 
studies were available. The applicant identified eight unpublished human intervention studies as 
pertinent to the claim (Petyaev et al., unpublished). One of these studies was published during the 
evaluation of the application (Petyaev et al., 2014). 
The eight human intervention studies provided were conducted with L-tug lycopene in different food 
matrices, followed similar protocols, and, as indicated by the applicant, were exploratory in nature. 
The Panel notes that the information provided was insufficient to allow a scientific evaluation of the 
studies, and therefore EFSA requested that the applicant provide the full study reports. In reply, the 
applicant indicated that no additional information on the studies existed. 
From the limited information available in the application, the Panel notes that the studies were not 
randomised and that some methodological aspects, such as the definition of primary outcome(s), 
power calculations, treatment of missing data, compliance or correction for multiplicity of outcomes 
were not considered in the study reports, possibly because of the exploratory nature of these studies, as 
claimed by the applicant. The Panel also notes that for one of the studies, a number of discrepancies 
exist between the version provided to EFSA (Petyaev et al., unpublished) and the published version 
(Petyaev et al., 2014) regarding the number of subjects included, the participant flow and the presence 
or absence of randomisation. The Panel considers that no conclusions can be drawn from these studies 
for the scientific evaluation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-tug lycopene and reduction of blood LDL-cholesterol concentrations. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, L-tug lycopene (i.e. Lyc-O-Mato® embedded in fat-rich matrices by a 
manufacturing process claimed as proprietary and confidential by the applicant), which is the 
subject of the health claim is sufficiently characterised. 
 The claimed effect is “lowering low-density lipoprotein (LDL)-cholesterol concentrations, 
which decreases the risk of coronary heart disease”. The target population as proposed by the 
applicant comprises “healthy adults who wish to lower their blood cholesterol levels”. 
Reduction of blood LDL-cholesterol concentrations is a beneficial physiological effect. A 
reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.  
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 A cause and effect relationship has not been established between the consumption of L-tug 
lycopene and reduction of blood LDL-cholesterol concentrations. 
DOCUMENTATION PROVIDED TO EFSA 
1. Health claim application on “L-tug lycopene” and reduction of blood LDL-cholesterol 
concentration pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 
0427_UK). August 2014. Submitted by Lycotec Ltd. 
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ABBREVIATIONS 
CHD  coronary heart disease 
HPLC  high-performance liquid chromatography 
LDL  low-density lipoprotein 
